Lead researcher
Prof Ricky Johnstone
Institution
Peter MacCallum Cancer Centre
Years funded
2012-2014
This project aims to identify new treatments for people with acute myeloid leukemia
(AML). AML is a disease that can be driven by changes in gene expression through a process called epigenetics. We aim to utilise pre-clinical models of human AML to test new agents that reverse the epigenetic changes that occur in this disease. Ultimately we aim to introduce these new treatment regimens into the clinic.
Lay Report - Final
Epigenetic-based therapies for AML
Funding Body
Cancer Council Research Grant
Funding
$98,723 per annum